Abstract
The effects of the antiparkinsonian agent trihexyphenidyl, a selective M1 muscarinic cholinergic receptor antagonist, were studied in doses of 100, 320 and 1000 μg/kg i.m. alone. Trihexyphenidyl was then studied in combination with the selective dopamine receptor D1 agonist SKF-82958 [(±)-6-chloro-7–8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzazepine hydrobromide] and the selective D2 agonist N-0923 [(−)2-(N-propyl-N-2-thienylethyl)amino-5-hydroxytetralin HCl] on rotational behavior in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned hemiparkinsonian monkeys. Given alone, trihexyphenidyl had no effect on ipsiversive and slightly enhanced contraversive circling. Contraversive circling produced by 74.8 and 234 μg/kg SKF-82958 i.m. was potentiated by increasing doses of trihexyphenidyl. On the other hand, contraversive circling produced by 10 and 32 μg/kg N-0923 i.m. was progressively reduced with increasing doses of trihexyphenidyl. The results obtained indicate differential actions on circling behavior between a selective M1 muscarinic cholinergic receptor antagonist and selective D1 and D2 receptor agonists in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkey model of hemiparkinsonism.
Footnotes
-
Send reprint requests to: Dr. E. F. Domino, Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109-0632.
-
↵1 This work was supported in part by Psychopharmacology Research Fund 361024.
-
↵2 E. F. Domino, unpublished observations.
- Abbreviations:
- 6-OHDA
- 6-hydroxydopamine
- MPTP
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- i.m.
- intramuscularly
- DA
- dopamine
- mAChR
- muscarinic cholinergic receptor
- NMDA
- N-methyl-d-aspartate
- ACh
- acetylcholine
- Received May 21, 1997.
- Accepted September 15, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|